Allergan, FDA communicate on Botox ads

Article

Irvine, Calif. - Allergan Inc., contrary to popular belief, isn't fighting the U.S. Food and Drug Administration's allegations that statements in Botox Cosmetic advertisements are misleading, thus violating of the Food, Drug, and Cosmetic Act.

Related Videos
Related Content

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

September 26th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

POLL: What Strategies Have You Found Most Effective in Managing Alopecia?

September 25th 2023

The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice

March 17th 2022

Hyaluronic Acid-Based Fillers Effective in Treating Signs of Aging

September 20th 2023

Pointers With Portela: What to Know About Ozempic

September 19th 2023

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

September 26th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

POLL: What Strategies Have You Found Most Effective in Managing Alopecia?

September 25th 2023

The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice

March 17th 2022

Hyaluronic Acid-Based Fillers Effective in Treating Signs of Aging

September 20th 2023

Pointers With Portela: What to Know About Ozempic

September 19th 2023

Phase 3 Trial Data Highlights Efficacy of OnabotulinutoxinA in Platysma Prominence

September 26th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

POLL: What Strategies Have You Found Most Effective in Managing Alopecia?

September 25th 2023

The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice

March 17th 2022

Hyaluronic Acid-Based Fillers Effective in Treating Signs of Aging

September 20th 2023

Pointers With Portela: What to Know About Ozempic

September 19th 2023
© 2023 MJH Life Sciences

All rights reserved.